Sustained virologic response to a dual peginterferon alfa-2a and ribavirin in treating chronic hepatitis c infection: A retrospective cohort study

Medicine (United States)

Volumn 94, Issue 30, 2015, Pages

  Naing, Cho ^a   Sitt, Than ^b   Aung, Aye Td ^b   Aung, Kyan ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b Option Endoscopy Centre Specialist Clinic   (Myanmar)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GALLSTONE; GENOTYPE; HUMAN; HYPERTENSION; INCIDENCE; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LIVER CIRRHOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYANMAR; NAUSEA; PERSONALITY DISORDER; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84942426365     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001234     Document Type: Article

References (45)

1. WHO. Hepatitis C. Fact sheet No.164. Updated April 2014. http: //www.who.int/mediacentre/factsheets/fs164/en/[January 12, 2015]
2. CDC. Chapter 3: Infectious diseases related to travel. 2013 http: //wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c [January 12, 2015]
3. Hanafiah KM, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57: 1333-1342.
4. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5: 558-567.
5. Nishikawa H, Iguchi E, Koshikawa Y, et al. The effect of pegylated interferon-Alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes. 2012; 5: 135.
6. AASLD. Understanding and Implementing the AASLDs 2009 Practice Guidelines on the Diagnosis, Management, and Treatment of Hepatitis C: An Update. 2009. http: //www.clinicaloptions.com/Hepatitis/Management%20Series/2009%20AASLD%20HCV%20Guidelines. aspx [January 12, 2015]
7. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011; 52: 889-890.
8. Susser S, Herrmann E, Lange C, et al. Predictive value of interferonlambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One. 2014; 9: e112592.
9. Koh C, Heller T, Haynes-Williams V, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferonbased therapy. Aliment Pharmacol Ther. 2013; 37: 887-894.
10. Nakai K, Win KM, Oo SS, et al. Molecular characteristic-based epidemiology of hepatitis B, C, and E viruses and GB virus C/hepatitis G virus in Myanmar. J Clin Microbiol. 2001; 39: 1536-1539.
11. Kuboki M, Iino S, Okuno T, et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol. 2007; 22: 645-652.
12. McHutchison JG, Lawitz EJ, Shiffman M, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361: 580-593.
13. Yee HS, Chang MF, Pocha C, et al., Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office. Update on the management and treatment of hepatitis C virus infection: recommendations from the department of veterans affairs hepatitis c resource center program and the national hepatitis c program office. Am J Gastroenterol. 2012; 107: 669-689.
14. Aziz H, Raza A, Waheed Y, et al. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. Int J Infect Dis. 2012; 16: e597-e602.
15. Pattullo V, Heathcote EJ, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int. 2010; 4: 723-731.
16. Gill U, Aziz H, Gill ML. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan. Int J Infect Dis. 2013; 17: e1017-e1021.
17. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009; 24: 336-345.
18. Bochud PY, Cai T, Overbeck K, et al. Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009; 51: 655-666.
19. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology (Baltimore, MD). 2002; 36: S114-S120.
20. AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C. 2014. (http: //www. aasld.org/publications/practice-guidelines-0#sthash.awnNL47N.dpuf [January 10, 2015]
21. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, MD). 2009; 49: 1335-1374.
22. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005; 43: 425-433.
23. Rong X, Xu R, Xiong H, et al. Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004-2007 and 2008-2011. Arch Virol. 2014; 159: 3231-3237Rong 2014.
24. Wasitthankasem R, Vongpunsawad S, Siripon N, et al. Genotypic distribution of hepatitis C virus in Thailand and southeast Asia. PLoS One. 2015; 10: e0126764.
25. Castera L, Hezode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004; 53: 420-424.
26. Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C. Minerva Gastroenterol Dietol. 2006; 52: 125-134.
27. Serfaty L, Andreani T, Giral P, et al. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001; 34: 428-434.
28. Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006; 55: 123-130.
29. Chen MY, Liu CH, Chen TC, et al. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. J Gastroenterol Hepatol. 2014; 29: 102-109.
30. Thong VD, Wasitthankasem R, Tangkijvanich P, et al. Prevalence of tymine-Adenine dinucleotide repeat, IL28B and IFNL4 in Thai population and correlation with spontaneous clearance and treatment outcome of hepatitis c infection. PLoS One. 2015; 10: e0125400.
31. Jia Z, Ding Y, Tian S, et al. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-Analysis. PLoS One. 2012; 7: e45698.
32. Watanabe T, Sugauchi F, Tanaka Y, et al. Hepatitis C virus kinetics by administration of pegylated interferon-A in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut. 2013; 62: 1340-1346.
33. Matsuura K, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J Gastroenterol Hepatol. 2014; 29: 241-249.
34. Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann Hepatol. 2010; 9 Suppl: 112-118.
35. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-Alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009; 50: 712-718.
36. Eslam M, Aparcero R, Kawaguchi T, et al. Meta-Analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011; 34: 297-305.
37. Jara P, Hierro L, de la Vega A, et al. Efficacy and safety of peginterferon-Alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J. 2008; 27: 142-148.
38. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology. 2000; 31: 1207-1211.
39. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000; 31: 997-1004.
40. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975-982.
41. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004; 53: 1504-2158.
42. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015; 64: 495-503doi: 10.1136/gutjnl-2014-308163.
43. Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 2009; 16: 295-308.
44. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology. 2014; 59: 71-77.
45. Saarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012; 56(Suppl 1): S88-S100.